Teva May Cut 10,000 Jobs

Published on: 11 Dec, 2017

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced the cut of 10,000 jobs as the company aims to reduce $1.5 billion to $2 billion in costs over the next two years. Following this announcement, the drug maker’s U.S. shares increased about 7% to $16.09. Teva is looking to send termination letters to “tens of percent” of their 10,000 workers in the U.S. Over the past year, the company has been dealing with almost $35 billion in debt following their $40.5 billion acquisition of Allergan Plc. After this deal, Teva’s profits have slumped and the previous CEO was forced to step down.

Chief Executive Officer Kare Schultz, who got control of the world’s biggest maker of generic drugs, has shook up the management team within days of becoming a CEO. Schultz has said he’ll present a detailed strategy plan in December for Teva’s financial recovery.

According to a report by Bloomberg Teva’s, “market value continues to languish at about $15.2 billion, or less than half of its debt burden, as competitors squeeze the profitability of its best-selling product and its generic drugs unit.”

Ratings

Ratings
  • 2007Views
  • 0Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Ariana Cheong

Email: ariana@financialinsiders.com

@Newsletter

Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Related Posts

12 Jul, 2017 2643
24 Aug, 2017 2438
07 Sep, 2017 2885
15 Sep, 2017 2494

Comments

There is no comment on this article